Future studies will be focused on developing the screening tests for miR-182 and mutant p53 expression in FTE cells for risk and non-risk populations and establishing a mouse model with overexpression of miR-182 and mutant p53 in FTE cells for ovarian cancer development. This evidence concerns the gene TP53 and ovarian carcinoma.